| Code | Description | Claims | Beneficiaries | Total Paid |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
10,913 |
9,699 |
$1.52M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
7,622 |
6,915 |
$848K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,383 |
1,219 |
$700K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
2,496 |
2,293 |
$511K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
8,905 |
3,282 |
$463K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
2,959 |
1,016 |
$360K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
3,136 |
2,833 |
$356K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
4,569 |
3,787 |
$330K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
821 |
674 |
$214K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,335 |
4,139 |
$147K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
4,585 |
1,886 |
$101K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,214 |
1,112 |
$94K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,227 |
1,072 |
$88K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,642 |
1,477 |
$85K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,346 |
1,853 |
$69K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
2,882 |
2,319 |
$54K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,801 |
1,600 |
$53K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
616 |
435 |
$49K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
10,100 |
8,358 |
$48K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,497 |
1,237 |
$44K |
| 71046 |
Radiologic examination, chest; 2 views |
1,871 |
1,782 |
$43K |
| 0002A |
|
1,261 |
936 |
$40K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
566 |
557 |
$39K |
| 0001A |
|
1,300 |
947 |
$38K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
289 |
285 |
$38K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,518 |
1,472 |
$35K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,518 |
1,472 |
$35K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
118 |
104 |
$32K |
| 97161 |
|
429 |
419 |
$28K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
699 |
365 |
$27K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,602 |
1,572 |
$26K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
3,820 |
3,413 |
$23K |
| 80053 |
Comprehensive metabolic panel |
6,656 |
5,809 |
$23K |
| ATP14 |
|
2,658 |
2,265 |
$21K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,380 |
2,295 |
$20K |
| 76801 |
|
124 |
113 |
$20K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
568 |
525 |
$19K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
118 |
110 |
$18K |
| ATP15 |
|
1,945 |
1,592 |
$18K |
| ATP08 |
|
2,451 |
2,118 |
$17K |
| 70450 |
Computed tomography, head or brain; without contrast material |
99 |
96 |
$16K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
2,674 |
2,429 |
$16K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
320 |
202 |
$14K |
| 84484 |
|
1,472 |
1,268 |
$14K |
| 90686 |
|
1,834 |
1,805 |
$13K |
| 97803 |
|
172 |
141 |
$13K |
| 85027 |
|
3,348 |
2,854 |
$13K |
| 81001 |
|
5,684 |
4,834 |
$12K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
6,448 |
5,479 |
$11K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
570 |
561 |
$10K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,111 |
1,050 |
$10K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,435 |
2,379 |
$10K |
| 97162 |
|
129 |
127 |
$9K |
| 87070 |
|
1,555 |
1,482 |
$9K |
| 81025 |
|
1,836 |
1,730 |
$9K |
| 87806 |
|
499 |
486 |
$9K |
| 86803 |
|
997 |
980 |
$8K |
| 83735 |
|
2,071 |
1,726 |
$8K |
| ATP17 |
|
943 |
853 |
$8K |
| 86618 |
|
715 |
699 |
$8K |
| 80050 |
General health panel |
607 |
605 |
$8K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
332 |
278 |
$7K |
| G0378 |
Hospital observation service, per hour |
48 |
44 |
$7K |
| 83655 |
|
701 |
684 |
$7K |
| 0004A |
|
177 |
171 |
$7K |
| 83690 |
|
1,382 |
1,253 |
$6K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
348 |
345 |
$6K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
106 |
106 |
$6K |
| 71045 |
Radiologic examination, chest; single view |
525 |
474 |
$6K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
39 |
39 |
$6K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
64 |
64 |
$6K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
372 |
369 |
$6K |
| 0012A |
|
167 |
139 |
$5K |
| 87276 |
|
490 |
475 |
$5K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
103 |
69 |
$4K |
| 0011A |
|
178 |
147 |
$4K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
85 |
78 |
$4K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
146 |
144 |
$4K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
674 |
607 |
$4K |
| 81003 |
|
2,016 |
1,595 |
$4K |
| 85610 |
|
1,623 |
987 |
$3K |
| J3490 |
Unclassified drugs |
483 |
405 |
$3K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
83 |
76 |
$3K |
| 87077 |
|
522 |
496 |
$3K |
| ATP03 |
|
594 |
538 |
$3K |
| 76830 |
Ultrasound, transvaginal |
38 |
38 |
$3K |
| 97802 |
|
38 |
38 |
$3K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
2,726 |
2,640 |
$3K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
14 |
14 |
$3K |
| 80306 |
|
247 |
214 |
$3K |
| 82728 |
|
327 |
317 |
$2K |
| 83605 |
|
276 |
249 |
$2K |
| 86850 |
|
288 |
267 |
$2K |
| 0124A |
|
44 |
44 |
$2K |
| 0071A |
|
52 |
42 |
$2K |
| 84702 |
|
164 |
114 |
$2K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
12 |
12 |
$2K |
| 80061 |
Lipid panel |
3,969 |
3,878 |
$2K |
| J2704 |
Injection, propofol, 10 mg |
734 |
697 |
$2K |
| 0064A |
|
45 |
44 |
$2K |
| 84439 |
|
271 |
262 |
$2K |
| 0072A |
|
35 |
35 |
$2K |
| 87186 |
|
253 |
243 |
$2K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
77 |
76 |
$1K |
| 83550 |
|
292 |
283 |
$1K |
| 85651 |
|
525 |
497 |
$1K |
| 84153 |
|
102 |
101 |
$1K |
| 87210 |
|
290 |
278 |
$1K |
| J7050 |
Infusion, normal saline solution, 250 cc |
691 |
434 |
$1K |
| 90670 |
|
25 |
25 |
$1K |
| 86140 |
|
276 |
256 |
$989.31 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,007 |
872 |
$938.30 |
| 82570 |
|
339 |
312 |
$899.81 |
| 87340 |
|
110 |
109 |
$891.56 |
| 83540 |
|
284 |
275 |
$863.90 |
| 86900 |
|
346 |
320 |
$861.38 |
| 73564 |
|
56 |
52 |
$849.39 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
34 |
26 |
$830.18 |
| 86901 |
|
330 |
305 |
$810.86 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,298 |
1,170 |
$726.42 |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
14 |
14 |
$705.74 |
| 73630 |
|
27 |
24 |
$694.05 |
| 85018 |
|
350 |
296 |
$683.15 |
| 0054A |
|
24 |
15 |
$642.18 |
| 87040 |
|
47 |
45 |
$623.34 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
757 |
724 |
$546.48 |
| 82607 |
|
64 |
64 |
$502.45 |
| 85014 |
|
253 |
244 |
$488.59 |
| 86756 |
|
40 |
40 |
$470.40 |
| 73130 |
|
16 |
13 |
$408.34 |
| ATP16 |
|
39 |
37 |
$405.18 |
| 86617 |
|
43 |
42 |
$384.03 |
| 87205 |
|
132 |
122 |
$343.07 |
| 73030 |
|
14 |
13 |
$317.28 |
| 73610 |
|
14 |
12 |
$306.26 |
| 90682 |
|
18 |
18 |
$280.18 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
374 |
304 |
$242.28 |
| 84403 |
|
13 |
12 |
$227.60 |
| 86592 |
|
71 |
71 |
$225.19 |
| 85379 |
|
27 |
24 |
$202.60 |
| 86780 |
|
15 |
15 |
$181.05 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
39 |
39 |
$178.17 |
| 86762 |
|
13 |
13 |
$170.69 |
| 86787 |
|
13 |
13 |
$152.75 |
| 80076 |
|
2,685 |
2,395 |
$145.88 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
142 |
137 |
$124.72 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
43 |
40 |
$121.14 |
| 83615 |
|
319 |
283 |
$105.30 |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
308 |
292 |
$101.11 |
| 87081 |
|
12 |
12 |
$70.20 |
| 87184 |
|
12 |
12 |
$62.90 |
| 82043 |
|
12 |
12 |
$42.24 |
| 82947 |
|
14 |
14 |
$38.17 |
| 85007 |
|
15 |
13 |
$28.17 |
| 84100 |
|
157 |
126 |
$21.46 |
| 84550 |
|
13 |
12 |
$4.12 |
| 36415 |
Collection of venous blood by venipuncture |
2,377 |
1,888 |
$3.23 |
| J2060 |
Injection, lorazepam, 2 mg |
18 |
12 |
$0.92 |
| 91300 |
|
2,586 |
1,713 |
$0.02 |
| 36416 |
|
554 |
477 |
$0.00 |
| 82962 |
|
440 |
368 |
$0.00 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
659 |
627 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
41 |
37 |
$0.00 |
| 91301 |
|
280 |
214 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
15 |
13 |
$0.00 |
| 87468 |
|
28 |
27 |
$0.00 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
18 |
13 |
$0.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
710 |
669 |
$0.00 |
| 91312 |
|
44 |
44 |
$0.00 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
187 |
159 |
$0.00 |
| 90633 |
|
31 |
26 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
15 |
14 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
45 |
37 |
$0.00 |
| 87469 |
|
14 |
14 |
$0.00 |
| 90734 |
|
13 |
13 |
$0.00 |